Health care startups that raised Series C in Asia
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| CureBay | Bhubaneshwar | Series C | $7.3M | 2026-10-22 |
| Caredoc | Gangneung | Series C | $39.3M | 2026-10-15 |
| Nat Habit | Gurgaon | Series C | $14.7M | 2026-10-10 |
| Nutshell Therapeutics | Shanghai | Series C | $40.0M | 2026-09-15 |
| QL Biopharma | Beijing | Series C | $44.7M | 2026-09-14 |
| Nua | Mumbai | Series C | $50.0M | 2026-09-07 |
| Kossel Medical | Suzhou | Series C | $59.5M | 2026-09-01 |
| AusperBio | Hangzhou | Series C | $120.0M | 2026-08-27 |
8 rows of the CSV in 5 of its 18 columns.
- The 461 health care startups in Asia whose last round is Series C have raised $14.1B in total.
- 60 of them closed their most recent round in the last 12 months, $1.6B combined.
- The largest of those rounds is AusperBio's $120.0M Series C, dated August 2026.
- The most recent is Trioar's $24.9M Series C on 22 October 2026.
- Shenzhen Capital Group is an investor in 5 of them, more than any other fund.
- Biotech is the most common other sector, with 205 companies (44%).
- 4% were founded in 2020 or later; the median founding year is 2015.
- The most common team size is 11 to 50 employees (31% of companies with a recorded size).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
30 of 461| Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| CureBay | CureBay provides healthcare, telemedicine, diagnostics, and pharmacy services. | Artificial intelligence | Bhubaneshwar, India | Series C | $7.3M | 2026-10-22 | $45.1M | Elevar Equity | 501 to 1,000 | 2021 |
| Caredoc | Caredoc runs an online platform that provides information on proven elderly care facilities. | Health care | Gangneung, South Korea | Series C | $39.3M | 2026-10-15 | $113.3M | TIPS Program, Korea Credit Guarantee Fund, Lotte Ventures | 11 to 50 | 2018 |
| Nat Habit | Nat Habit is a beauty and wellness brand that sells natural skincare products. | Health care | Gurgaon, India | Series C | $14.7M | 2026-10-10 | $30.9M | Titan Capital, Surge, Whiteboard Capital +1 | 101 to 250 | 2018 |
| Nutshell Therapeutics | Nutshell Therapeutics discovers small-molecule drugs using insights from protein dynamics. | Artificial intelligence | Shanghai, China | Series C | $40.0M | 2026-09-15 | $75.2M | Matrix Partners China, Source Code Capital, Northern Light Venture Capital +1 | 51 to 100 | 2013 |
| QL Biopharma | QL Biopharma develops recombinant protein drugs to treat chronic metabolic diseases. | Biotech | Beijing, China | Series C | $44.7M | 2026-09-14 | $173.7M | Chengdu Science and Technology Venture Capital, TF Capital, Lichen Capital +1 | 101 to 250 | 2018 |
| Nua | Nua sells customizable sanitary products as part of its women's wellness and hygiene brand. | Commerce | Mumbai, India | Series C | $50.0M | 2026-09-07 | $66.5M | Kae Capital, Lightbox | 51 to 100 | 2017 |
| Kossel Medical | Kossel Medical develops and manufactures vascular interventional devices and clinical system solutions. | Health care | Suzhou, China | Series C | $59.5M | 2026-09-01 | $103.0M | Fortune Venture Capital, Suzhou International Development Venture Capital, Ming Bioventures +1 | 501 to 1,000 | 2013 |
| AusperBio | AusperBio develops oligonucleotide therapeutics and targeted delivery technologies for treating diseases. | Biotech | Hangzhou, China | Series C | $120.0M | 2026-08-27 | $357.0M | Qiming Venture Partners, BioVenture, Hankang Capital +1 | 51 to 100 | 2019 |
| Diyingjia Technology | Diyingjia Technology develops artificial intelligence software for medical imaging and treatment applications. | Artificial intelligence | Beijing, China | Series C | $3.0M | 2026-07-28 | $32.3M | IDG Capital, Legend Capital, Microsoft Accelerator | 11 to 50 | 2017 |
| Delova Biotech | Delova Biotech develops treatments for pain management. | Biotech | Qixia, China | Series C | $88.6M | 2026-07-22 | $109.8M | Legend Capital, Peakview Capital, Hyfinity Investments +1 | 51 to 100 | 2017 |
| Weikaier Pharmaceutical Technology | Weikaier Pharmaceutical Technology conducts drug research, transfers generic drug technology, and produces and sells pharmaceuticals. | Biotech | Nanjing, China | Series C | $29.6M | 2026-06-02 | $120.4M | SDIC Venture Capital, Dyee Capital, Nanjing Innovation Capital Group +1 | 501 to 1,000 | 2010 |
| YolTech Therapeutics | YolTech Therapeutics combines LNP delivery with gene editing technology for biotechnology applications. | Biotech | Minhang, China | Series C | $73.8M | 2026-05-29 | $144.9M | K2VC, UnityVC, Decheng Capital +1 | 11 to 50 | 2021 |
| Butterfly Medical | Butterfly Medical offers a fast, non-invasive alternative treatment for benign prostate hyperplasia. | Health care | Yoqne`am `illit, Israel | Series C | $21.0M | 2026-05-14 | $30.1M | MassChallenge, MedTech Innovator, New Rhein +1 | 1 to 10 | 2014 |
| Caring | Caring provides visiting medical treatment and senior care services for elderly individuals. | Health care | Gangneung, South Korea | Series C | $27.3M | 2026-05-08 | $84.3M | KB Investment, IMM Investment, SV Investment Corp +1 | 101 to 250 | 2019 |
| Biobot Surgical Pte Ltd | Biobot Surgical provides minimally invasive robotic healthcare solutions worldwide. | Fintech | Singapore | Series C | $7.8M | 2026-04-09 | $39.6M | ZIG Ventures | 11 to 50 | 2010 |
| Ruining Bio | Ruining Bio provides clinical medical solutions such as tumor radiotherapy protection and wound repair. | Health care | Jiading, China | Series C | $14.6M | 2026-02-28 | $38.8M | Qiming Venture Partners, Taiyu Investment, Dingxin Capital +1 | 2018 | |
| Supertails | Supertails runs a digital pet care platform offering pet products, services, and online veterinary consultations. | Health care | Bangalore, India | Series C | $30.0M | 2026-02-09 | $58.4M | Titan Capital, Alteria Capital, Whiteboard Capital +1 | 101 to 250 | 2021 |
| Pee Safe | Pee Safe makes hygiene products, such as sanitary and personal care items, for customers across India. | Health care | Gurgaon, India | Series C | $32.0M | 2026-01-14 | $44.7M | Venture Catalysts, Rainmatter Capital | 101 to 250 | 2013 |
| Zenitar | Zenitar conducts drug research and biomedical technology industrialization. | Biotech | Chengdu, China | Series C | $86.0M | 2026-01-12 | $155.7M | Si Chuan Venture Capital, Chengdu High-tech Ceyuan Capital, New Value Capital | 51 to 100 | 2019 |
| Darwin Cell Biology | Darwin Cell Biology provides cell biotechnology services. | Biotech | Beijing, China | Series C | $27.9M | 2025-12-08 | $62.4M | Shijingshan Modern Innovation Industry Fund, Shanghai Yungu Investment | 11 to 50 | 2016 |
| AITRICS | AITRICS delivers AI-powered medical software that helps clinicians detect and prevent critical patient deterioration. | Artificial intelligence | Seoul, South Korea | Series C | $23.8M | 2025-12-01 | $50.9M | Springcamp, HB Investment, Premier Partners +1 | 51 to 100 | 2016 |
| Healsun Biopharm | Healsun Biopharm provides antibody and recombinant protein CRO and CDMO services. | Biotech | Hangzhou, China | Series C | $27.8M | 2025-11-19 | $101.3M | Yinxinggu Capital, Haitong Capital, Dongfang Jiafu +2 | 251 to 500 | 2015 |
| GRIT Biotechnology | GRIT Biotechnology develops tumor infiltrating lymphocyte immunotherapy for solid tumors. | Biotech | Shanghai, China | Series C | $84.0M | 2025-10-14 | $153.5M | Matrix Partners China, Hillhouse Investment, CICC +2 | 51 to 100 | 2019 |
| Yantai Lannacheng Biotechnology | Yantai Lannacheng Biotechnology develops Class I diagnostic medications. | Biotech | Yantai, China | Series C | $41.8M | 2025-07-20 | $103.8M | Shenzhen Capital Group, Qianhai Fund of Funds, Yuanhe Capital +1 | 1 to 10 | 2021 |
| Tianchen Biotechnology | Tianchen Biotechnology develops and sells medical products for ophthalmology. | Biotech | Tianjin, China | Series C | $27.8M | 2025-06-03 | $41.7M | CMB International Capital Corporation | 2018 | |
| LongBio Pharma | LongBio Pharma develops treatments for patients with complement and allergy diseases. | Biotech | Pudong, China | Series C | $28.9M | 2025-05-27 | $51.1M | Oriental Fortune Capital, Shanxi Securities Investment, Hefei Hongda +2 | 11 to 50 | 2020 |
| CURAUM | CURAUM makes oral care and sleep-related health care products. | Health care | Daejeon, South Korea | Series C | $14.6M | 2025-05-25 | $23.3M | TIPS Program, Korea Credit Guarantee Fund, Lotte Ventures | 11 to 50 | 2017 |
| Foxtale | Foxtale sells skincare products suited to all skin types. | Health care | Mumbai, India | Series C | $30.0M | 2025-01-15 | $67.1M | Z47, Kae Capital, Stride Ventures | 51 to 100 | 2021 |
| Imagoworks | Imagoworks develops AI and cloud-based 3D dental and medical software. | Artificial intelligence | Seocho, South Korea | Series C | $15.6M | 2024-12-31 | $25.9M | KB Investment, Company K Partners, LB Investment +2 | 51 to 100 | 2019 |
| NitiNotes | NitiNotes develops the EndoZip automated suturing device for obesity treatment. | Health care | Caesarea, Israel | Series C | $9.3M | 2024-12-23 | Elron Ventures, Peregrine Ventures, MTIP AG | 11 to 50 | 2014 |
Table 1. Health care startups that raised Series C in Asia: the 30 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 461.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AusperBio | AusperBio develops oligonucleotide therapeutics and targeted delivery technologies for treating diseases. | Biotech | Hangzhou, China | Series C | $120.0M | 2026-08-27 | $357.0M | Qiming Venture Partners, BioVenture, Hankang Capital +1 | 51 to 100 | 2019 |
| 2 | Delova Biotech | Delova Biotech develops treatments for pain management. | Biotech | Qixia, China | Series C | $88.6M | 2026-07-22 | $109.8M | Legend Capital, Peakview Capital, Hyfinity Investments +1 | 51 to 100 | 2017 |
| 3 | Zenitar | Zenitar conducts drug research and biomedical technology industrialization. | Biotech | Chengdu, China | Series C | $86.0M | 2026-01-12 | $155.7M | Si Chuan Venture Capital, Chengdu High-tech Ceyuan Capital, New Value Capital | 51 to 100 | 2019 |
| 4 | YolTech Therapeutics | YolTech Therapeutics combines LNP delivery with gene editing technology for biotechnology applications. | Biotech | Minhang, China | Series C | $73.8M | 2026-05-29 | $144.9M | K2VC, UnityVC, Decheng Capital +1 | 11 to 50 | 2021 |
| 5 | Kossel Medical | Kossel Medical develops and manufactures vascular interventional devices and clinical system solutions. | Health care | Suzhou, China | Series C | $59.5M | 2026-09-01 | $103.0M | Fortune Venture Capital, Suzhou International Development Venture Capital, Ming Bioventures +1 | 501 to 1,000 | 2013 |
| 6 | Nua | Nua sells customizable sanitary products as part of its women's wellness and hygiene brand. | Commerce | Mumbai, India | Series C | $50.0M | 2026-09-07 | $66.5M | Kae Capital, Lightbox | 51 to 100 | 2017 |
| 7 | QL Biopharma | QL Biopharma develops recombinant protein drugs to treat chronic metabolic diseases. | Biotech | Beijing, China | Series C | $44.7M | 2026-09-14 | $173.7M | Chengdu Science and Technology Venture Capital, TF Capital, Lichen Capital +1 | 101 to 250 | 2018 |
| 8 | Nutshell Therapeutics | Nutshell Therapeutics discovers small-molecule drugs using insights from protein dynamics. | Artificial intelligence | Shanghai, China | Series C | $40.0M | 2026-09-15 | $75.2M | Matrix Partners China, Source Code Capital, Northern Light Venture Capital +1 | 51 to 100 | 2013 |
| 9 | Caredoc | Caredoc runs an online platform that provides information on proven elderly care facilities. | Health care | Gangneung, South Korea | Series C | $39.3M | 2026-10-15 | $113.3M | TIPS Program, Korea Credit Guarantee Fund, Lotte Ventures | 11 to 50 | 2018 |
| 10 | Pee Safe | Pee Safe makes hygiene products, such as sanitary and personal care items, for customers across India. | Health care | Gurgaon, India | Series C | $32.0M | 2026-01-14 | $44.7M | Venture Catalysts, Rainmatter Capital | 101 to 250 | 2013 |
Table 2. Health care startups that raised Series C in Asia: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | Shenzhen Capital Group | Venture capital firm | Nanshan, China | 5 | 1% | ||
| 2 | Matrix Partners China | Venture capital firm | Beijing, China | 4 | 1% | 1 | Nutshell Therapeutics |
| 3 | Qiming Venture Partners | Venture capital firm | Shanghai, China | 4 | 1% | 2 | AusperBio, Ruining Bio |
| 4 | Legend Capital | Venture capital firm | Beijing, China | 4 | 1% | 2 | Diyingjia Technology, Delova Biotech |
| 5 | OrbiMed | Private equity firm | New York, United States | 4 | 1% | 1 | Shenluo Medical |
| 6 | Shanghai Biomedical Industrial Equity Investment Fund | Venture capital firm | Huangpu, China | 4 | 1% | 1 | Healsun Biopharm |
| 7 | Hillhouse Investment | Angel group | Singapore | 4 | 1% | ||
| 8 | SMBC Venture Capital | Corporate venture arm | Tokyo, Japan | 4 | 1% | ||
| 9 | Shenzhen Guozhong Venture Capital Management | Venture capital firm | Shenzhen, China | 4 | 1% | ||
| 10 | TIPS Program | Startup incubator | Gangneung, South Korea | 3 | 1% | 1 | Caredoc |
| 11 | Fireside Ventures | Micro VC fund | Bangalore, India | 3 | 1% | 2 | Nat Habit, Supertails |
| 12 | Whiteboard Capital | Venture capital firm | Mumbai, India | 3 | 1% | 2 | Nat Habit, Supertails |
| 13 | Baidu Ventures | Venture capital firm | Beijing, China | 3 | 1% | 1 | Nutshell Therapeutics |
| 14 | Northern Light Venture Capital | Venture capital firm | Beijing, China | 3 | 1% | 1 | Nutshell Therapeutics |
| 15 | Fortune Venture Capital | Venture capital firm | Shenzhen, China | 3 | 1% | 1 | Kossel Medical |
Table 3. Health care startups that raised Series C in Asia: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
Table 4. Health care startups that raised Series C in Asia by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Series C | 461 | 100% | $18.0M |
Table 5. Health care startups that raised Series C in Asia by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Countries
| Countries | Companies | Share |
|---|---|---|
| China | 309 | 67% |
| South Korea | 52 | 11% |
| Japan | 31 | 7% |
| Israel | 27 | 6% |
| India | 22 | 5% |
| Singapore | 9 | 2% |
| Taiwan | 5 | 1% |
| United Arab Emirates | 2 | 0% |
| Indonesia | 1 | 0% |
| Hong Kong | 1 | 0% |
| Thailand | 1 | 0% |
| Jordan | 1 | 0% |
Table 6. Health care startups that raised Series C in Asia by headquarters country. Source: FundingWatcher. Data as of 16 November 2026.
Cities
Table 7. Health care startups that raised Series C in Asia by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| October 2026 | 5 | 8% | $116.2M |
| September 2026 | 5 | 8% | $234.2M |
| August 2026 | 3 | 5% | $157.1M |
| July 2026 | 6 | 10% | $192.2M |
| June 2026 | 3 | 5% | $73.8M |
| May 2026 | 9 | 15% | $243.6M |
| April 2026 | 4 | 7% | $131.4M |
| March 2026 | 7 | 12% | $83.1M |
| February 2026 | 5 | 8% | $132.6M |
| January 2026 | 4 | 7% | $118.0M |
| December 2025 | 8 | 13% | $88.7M |
| November 2025 | 1 | 2% | $27.8M |
Table 8. Health care startups that raised Series C in Asia: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 51 | 11% | $1.5B |
| 2025 | 55 | 12% | $1.1B |
| 2024 | 50 | 11% | $623.2M |
| 2023 | 45 | 10% | $841.2M |
| 2022 | 47 | 10% | $892.4M |
| 2021 | 77 | 17% | $3.8B |
Table 9. Health care startups that raised Series C in Asia by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2020 to 2022 | 20 | 4% |
| 2015 to 2019 | 211 | 46% |
| 2010 to 2014 | 151 | 33% |
| Before 2010 | 76 | 17% |
Table 10. Health care startups that raised Series C in Asia by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 37 | 8% |
| 11 to 50 | 136 | 31% |
| 51 to 100 | 87 | 20% |
| 101 to 250 | 82 | 19% |
| 251 to 500 | 42 | 10% |
| 501 to 1,000 | 31 | 7% |
| 1,001 to 5,000 | 19 | 4% |
| 5,001 to 10,000 | 2 | 0% |
| 10,001 or more | 1 | 0% |
Table 11. Health care startups that raised Series C in Asia by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Health care is one of its sectors and its most recent funding round is Series C and its headquarters is in Asia. On 16 November 2026 that is 461 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 30 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 461 rows: 94 have no round amount, 0 no city and 123 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many health care startups in Asia whose last round is Series C are on the list?
- 461, in the file dated 16 November 2026. 60 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 461 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.